Literature DB >> 28114637

High Prices for Drugs With Generic Alternatives: The Curious Case of Duexis.

Aaron Hakim1, Joseph S Ross2.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 28114637     DOI： 10.1001/jamainternmed.2016.8423

Source DB:  PubMed          Journal:  JAMA Intern Med        ISSN： 2168-6106            Impact factor:   21.873


× No keyword cloud information.
  5 in total

1.  Medicare Spending on Brand-name Combination Medications vs Their Generic Constituents.

Authors:  Chana A Sacks; ChangWon C Lee; Aaron S Kesselheim; Jerry Avorn
Journal:  JAMA       Date:  2018-08-21       Impact factor: 56.272

2.  Approvals and Timing of New Formulations of Novel Drugs Approved by the US Food and Drug Administration Between 1995 and 2010 and Followed Through 2021.

Authors:  Ravi Gupta; Christopher J Morten; Angela Y Zhu; Reshma Ramachandran; Nilay D Shah; Joseph S Ross
Journal:  JAMA Health Forum       Date:  2022-05-20

3.  Association between dispensing of low-value oral albuterol and removal from Medicaid preferred drug lists.

Authors:  Anna Volerman; Alison Pelczar; Rena Conti; Christina Ciaccio; Kao-Ping Chua
Journal:  BMC Health Serv Res       Date:  2022-04-26       Impact factor: 2.908

4.  Association between industry payments and prescribing costly medications: an observational study using open payments and medicare part D data.

Authors:  Manvi Sharma; Aisha Vadhariya; Michael L Johnson; Zachary A Marcum; Holly M Holmes
Journal:  BMC Health Serv Res       Date:  2018-04-02       Impact factor: 2.655

5.  How to prevent the next Marathon Pharmaceuticals.

Authors:  Frank S David; Richa Dixit
Journal:  F1000Res       Date:  2018-01-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.